cilostazol has been researched along with Cerebral Arteriosclerosis in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Changes in atherosclerosis are more dynamic in patients with symptomatic ICAS, and the predictors of symptomatic and asymptomatic ICAS differ." | 2.79 | Predictors of symptomatic and asymptomatic intracranial atherosclerosis: what is different and why? ( Cho, YJ; Hong, KS; Kang, DW; Kim, BJ; Kim, JS; Koo, JS; Kwon, SU; Lee, JH; Lee, SH; Park, JM, 2014) |
| "Intracranial arterial stenosis (IAS) is the cause of about 10% of all ischemic strokes in the United States, but may account for about 40% of strokes in some populations." | 2.47 | Current management of symptomatic intracranial stenosis. ( Kasner, SE; Taylor, RA; Weigele, JB, 2011) |
| "Cilostazol is an antiplatelet drug often used in Asian countries like Korea, Japan, and China." | 1.42 | Cilostazol research in Asia: can it be applied to European and American patients? ( Kim, JS; Kwon, SU; Uchiyama, S, 2015) |
| "Cilostazol is an antiplatelet drug often used in Asia; however, it is rarely used in the western hemisphere, particularly for stroke patients." | 1.37 | Cilostazol: a drug particularly effective for Asians? ( Kim, JS; Shinohara, Y, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Uchiyama, S | 2 |
| Toyoda, K | 1 |
| Omae, K | 1 |
| Saita, R | 1 |
| Kimura, K | 1 |
| Hoshino, H | 1 |
| Sakai, N | 1 |
| Okada, Y | 1 |
| Tanaka, K | 1 |
| Origasa, H | 1 |
| Naritomi, H | 1 |
| Houkin, K | 1 |
| Yamaguchi, K | 1 |
| Isobe, M | 1 |
| Minematsu, K | 1 |
| Matsumoto, M | 1 |
| Tominaga, T | 1 |
| Tomimoto, H | 1 |
| Terayama, Y | 1 |
| Yasuda, S | 1 |
| Yamaguchi, T | 1 |
| Kim, BJ | 1 |
| Hong, KS | 2 |
| Cho, YJ | 2 |
| Lee, JH | 2 |
| Koo, JS | 2 |
| Park, JM | 2 |
| Kang, DW | 2 |
| Kim, JS | 4 |
| Lee, SH | 2 |
| Kwon, SU | 3 |
| Gomez, CR | 1 |
| Qureshi, AI | 1 |
| Khan, M | 1 |
| Kamal, AK | 1 |
| Shinohara, Y | 1 |
| Taylor, RA | 1 |
| Weigele, JB | 1 |
| Kasner, SE | 1 |
| Yu, KH | 1 |
| Wong, KS | 1 |
| Lee, KB | 1 |
| Kim, DE | 1 |
| Jeong, SW | 1 |
| Bae, HJ | 1 |
| Lee, BC | 1 |
| Han, MK | 1 |
| Rha, JH | 1 |
| Kim, HY | 1 |
| Mok, VC | 1 |
| Lee, YS | 1 |
| Kim, GM | 1 |
| Suwanwela, NC | 1 |
| Yun, SC | 1 |
| Nah, HW | 1 |
| Yamamoto, Y | 1 |
| Ohara, T | 1 |
| Nagakane, Y | 1 |
| Tanaka, E | 1 |
| Morii, F | 1 |
| Koizumi, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370] | Phase 4 | 1,884 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
| Trial for Efficacy and Safety of Cilostazol on the Progression of Symptomatic Intracranial Stenosis Comparing Clopidogrel[NCT00130039] | Phase 4 | 457 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
number of patients with new ischemic lesions on FLAIR (Fluid attenuation inversion recovery) images of follow-up MRI, which were determined by slice to slice comparison with baseline MRI. (NCT00130039)
Timeframe: 7 months after treatment
| Intervention | pariticipants (Number) |
|---|---|
| Cilostazol | 34 |
| Clopidogrel | 23 |
including nonfatal stroke, nonfatal myocardial infarction and vascular death. (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 15 |
| Clopidogrel | 10 |
"Blind reviewers classified the presence and severity of stenosis on middle cerebral arteries and basilar artery on magnetic resonance angiogram (MRA) into 5 grades; normal, mild, moderate, severe and occlusion. Progression was defined as worsening of stenosis by 1 or more grades on final MRA as compared with the baseline MRA.~The progression of symptomatic stenosis is defined as 1 or more grade worsening of the stenosis on the symptomatic artery on MRA." (NCT00130039)
Timeframe: 7 months after treatment
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 20 |
| Clopidogrel | 32 |
including nonfatal ischemic stroke, nonfatal hemorrhagic stroke and fatal stroke (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 11 |
| Clopidogrel | 7 |
ischemic stroke event which occured in the vascular territory of initial symptomatic stenosis (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | participants (Number) |
|---|---|
| Cilostazol | 9 |
| Clopidogrel | 5 |
life-threatening or fatal bleeding was defined as any fatal bleeding event, a drop in hemoglobin of ≥ 50g/L, or significant hypotension with need for inotropic agents, symptomatic intracranial hemorrhage, or transfusion of ≥ 4 units of red-blood cells or equivalent amount of whole blood. Major bleeding was defined as significantly disabling bleedings, intraocular bleeding leading to significant visual loss, or bleeding requiring transfusion of ≤ 3 units of red-blood cells or equivalent amount of whole blood (NCT00130039)
Timeframe: upto 7 months after randomization
| Intervention | events (Number) |
|---|---|
| Cilostazol | 2 |
| Clopidogrel | 6 |
2 reviews available for cilostazol and Cerebral Arteriosclerosis
| Article | Year |
|---|---|
Current management of symptomatic intracranial stenosis.
Topics: Angioplasty; Anticoagulants; Atorvastatin; Brain; Brain Ischemia; Cilostazol; Constriction, Patholog | 2011 |
[Concept of branch atheromatous disease (BAD) and its clinical significance].
Topics: Antipyrine; Arginine; Cerebral Infarction; Cilostazol; Drug Therapy, Combination; Edaravone; Humans; | 2010 |
3 trials available for cilostazol and Cerebral Arteriosclerosis
| Article | Year |
|---|---|
Dual Antiplatelet Therapy Using Cilostazol in Patients With Stroke and Intracranial Arterial Stenosis.
Topics: Cilostazol; Drug Therapy, Combination; Humans; Intracranial Arteriosclerosis; Platelet Aggregation I | 2021 |
Predictors of symptomatic and asymptomatic intracranial atherosclerosis: what is different and why?
Topics: Aged; Arteries; Atherosclerosis; Cholesterol, HDL; Cilostazol; Constriction, Pathologic; Disease Pro | 2014 |
Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis.
Topics: Aged; Aged, 80 and over; Cilostazol; Clopidogrel; Constriction, Pathologic; Disease Progression; Dou | 2011 |
4 other studies available for cilostazol and Cerebral Arteriosclerosis
| Article | Year |
|---|---|
Cilostazol research in Asia: can it be applied to European and American patients?
Topics: Asia; Cilostazol; Europe; Hemorrhage; Humans; Intracranial Arteriosclerosis; Phosphoric Diester Hydr | 2015 |
Medical treatment of patients with intracranial atherosclerotic disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb | 2009 |
What are the therapeutic options for strokes secondary to intracranial large artery stenosis?
Topics: Anticoagulants; Aspirin; Cilostazol; Evidence-Based Medicine; Humans; Intracranial Arteriosclerosis; | 2011 |
Cilostazol: a drug particularly effective for Asians?
Topics: Aryl Hydrocarbon Hydroxylases; Asian People; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders | 2011 |